Balyasny Asset Management’s Cidara Therapeutics CDTX Stock Holding History

Balyasny Asset Management’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-74,400	Closed	-$16.4M	–	2943
2025 Q4	$16.4M	Buy	+74,400	New	+$12M	0.02%	816

Balyasny Asset Management's CDTX Position: Q1 2026 in Review

Balyasny Asset Management sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 672,890 shares — an estimated $149M sold.

Balyasny Asset Management first reported a position in CDTX in Q1 2018 and held it in 4 quarters. The position peaked at $149M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Balyasny Asset Management reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Balyasny Asset Management sold 672,890 Cidara Therapeutics shares in Q1 2026, an estimated $149M.
Balyasny Asset Management first reported a position in Cidara Therapeutics in Q1 2018 and held it in 4 quarters.
Balyasny Asset Management's Cidara Therapeutics position peaked at $149M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.